Karyopharm Therapeutics Inc. KPTI PHARMA
Company Overview
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Why Investors Should Care
Generates a return on equity of 66.9%, reflecting efficient use of shareholder capital.
Revenue has grown at a 63.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $146.07M (+0.6% YoY); net profit $-196.04M.
- Trailing 12 Months Year-on-year growth — revenue -11.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 63.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 63.32% |
| 1 Year: | -11.90% |
Stock Price Performance
| 1 Year: | -61.35% |
| 6 Months: | -79.74% |
| 3 Months: | -79.76% |
| 1 Month: | -18.87% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)26.72 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 66.9%.
- Compounding revenue at 63.3% over 5 years.
CONS
- Trading 83.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KPTI Karyopharm Therapeutics Inc. PHARMA | 1.72 | -0.12 | $39.01M | 0.00% | - | 66.92% | 63.32% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 3.00K | - | - | 10.00M | 19.89M | 239.00K | - | 155.00K | 9.49M | 13.15M | 18.14M | 33.51M | 21.33M | 23.26M | 22.60M | 37.69M | 47.67M | 39.68M | 36.15M | 38.70M | 37.58M | 36.01M | 33.13M | 42.79M | 38.78M | 30.02M | 37.93M | 44.04M | 35.07M |
| Operating Income | -19.74M | -25.94M | -26.15M | -33.01M | -30.61M | -29.30M | -27.35M | -30.48M | -25.74M | -27.16M | -30.28M | -29.75M | -31.05M | -39.45M | -38.94M | -34.33M | -49.15M | -57.45M | -64.92M | -41.69M | -39.40M | -47.36M | -40.32M | -47.11M | -52.37M | -49.05M | -43.81M | -34.59M | -42.91M | -30.84M | -30.90M | -29.57M | -31.26M | -33.76M | -28.12M | -26.28M | -33.26M | -24.39M | -15.22M | -26.76M |
| Net Income | -19.72M | -25.93M | -26.07M | -32.70M | -30.37M | -29.05M | -27.06M | -30.16M | -25.43M | -26.93M | -29.92M | -29.39M | -30.64M | -39.04M | -38.46M | -33.66M | -48.08M | -58.21M | -66.16M | -43.41M | -41.37M | -52.93M | -46.43M | -53.49M | -57.41M | -53.58M | -51.81M | -41.40M | -49.06M | -36.32M | -34.13M | -32.63M | -34.51M | -37.36M | 23.79M | -32.07M | -23.46M | -37.25M | -33.13M | -22.39M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.71 | -0.69 | -0.53 | -0.62 | -0.45 | -0.30 | -0.29 | -0.30 | -4.85 | -2.97 | -3.85 | -2.77 | -4.32 | -3.82 | -1.24 |
| R&D Expense | 15.95M | - | 20.75M | 27.01M | 25.92M | - | 21.80M | 24.58M | 19.89M | - | 24.08M | 23.12M | 25.24M | - | 41.32M | 44.73M | 36.43M | - | 37.97M | 26.52M | 26.27M | 34.00M | 42.59M | 37.04M | 37.05M | 33.98M | 45.81M | 42.06M | 44.31M | 31.36M | 32.34M | 31.48M | 35.55M | 35.42M | 38.37M | 36.13M | 34.62M | 32.79M | 30.54M | 33.80M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 152.00K | 634.00K | 387.00K | 229.00K | 250.00K | 154.00K | 1.60M | 30.34M | 40.89M | 108.08M | 209.82M | 157.07M | 146.03M | 145.24M | 146.07M |
| Operating Income | - | - | -10.31M | -15.89M | -33.95M | -75.85M | -119.08M | -110.73M | -130.54M | -179.88M | -189.28M | -171.85M | -98.27M | -142.20M | -129.54M | -119.44M | -90.71M |
| Net Income | -179.00K | -2.24M | -10.31M | -15.89M | -33.95M | -75.78M | -118.18M | -109.58M | -128.98M | -178.41M | -199.59M | -196.27M | -124.09M | -165.29M | -143.10M | -76.42M | -196.04M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -2.72 | -1.65 | -2.02 | -18.79 | -14.00 | -17.93 |
| R&D Expense | - | - | 8.62M | 14.10M | 28.45M | 60.13M | 97.74M | 86.94M | 107.27M | 161.37M | 122.34M | 150.81M | 160.84M | 148.66M | 138.75M | 143.23M | 125.62M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 1.31M | 158.23M | 220.34M | 215.44M | 180.38M | 180.29M | 341.19M | 294.96M | 313.05M | 305.31M | 358.17M | 240.44M | 164.42M | 108.42M |
| Total Equity | -179.00K | -2.38M | -12.65M | -27.88M | 154.93M | 206.79M | 198.37M | 162.24M | 129.46M | 183.17M | 49.77M | 50.55M | -79.67M | -16.66M | -136.21M | -186.02M | -292.93M |
| Cash & Equivalents | - | 3.44M | 6.51M | 391.00K | 155.97M | 150.61M | 58.36M | 49.66M | 69.00M | 118.02M | 128.86M | 85.92M | 190.46M | 135.19M | 52.23M | 62.48M | 60.54M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | 169.29M | - | - | - | - |
| Total Liabilities | - | - | - | - | 3.29M | 13.54M | 17.08M | 18.14M | 50.83M | 158.02M | 245.19M | 262.50M | 384.98M | 374.83M | 376.64M | 350.44M | 401.34M |
| Current Liabilities | - | - | - | 1.93M | 3.29M | 12.30M | 15.13M | 16.48M | 49.47M | 46.90M | 46.35M | 60.20M | 73.72M | 65.91M | 69.48M | 92.26M | 92.06M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | -84.39M | -73.72M | -159.12M | -190.82M | -160.23M | -107.12M | -149.55M | -92.72M | -127.49M | -75.37M |
| Investing Cash Flow | - | - | - | - | - | 24.59M | 17.11M | -107.66M | 78.45M | -53.69M | 141.84M | -104.26M | 7.94M | 95.47M | 43.38M |
| Financing Cash Flow | - | - | - | - | - | 51.16M | 75.74M | 316.11M | 124.31M | 172.08M | 73.65M | 193.74M | 1.12M | 41.65M | 30.05M |
| Capital Expenditure | -376.00K | -121.00K | -57.00K | -2.83M | -1.42M | -70.00K | -62.00K | -2.36M | -206.00K | -145.00K | -212.00K | -118.00K | -0 | -142.00K | -0 |
| Free Cash Flow | - | - | - | - | - | -84.46M | -73.78M | -161.48M | -191.03M | -160.38M | -107.33M | -149.67M | -92.72M | -127.63M | -75.37M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -6,783.6% | -2,506.3% | -8,772.6% | -33,120.5% | -47,630.4% | -71,903.9% | -8,133.2% | -593.0% | -462.9% | -159.0% | -46.8% | -90.5% | -88.7% | -82.2% | -62.1% |
| Net Margin % | - | - | -6,783.6% | -2,506.0% | -8,771.8% | -33,090.4% | -47,272.4% | -71,153.9% | -8,036.4% | -588.1% | -488.1% | -181.6% | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% |
| ROE % | 100.0% | 94.4% | 81.5% | 57.0% | -21.9% | -36.6% | -59.6% | -67.5% | -99.6% | -97.4% | -401.0% | -388.3% | 155.7% | 992.4% | 105.1% | 41.1% | 66.9% |
| ROCE % | - | - | - | 2,567.0% | -21.9% | -36.5% | -59.4% | -67.6% | -99.8% | -61.1% | -76.1% | -68.0% | -42.4% | -48.7% | -75.8% | -165.5% | -554.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 8.45% | 1.92M | $3.60M |
| 2 | Adage Capital Partners GP L.L.C. | 6.71% | 1.52M | $2.86M |
| 3 | Acorn Capital Advisors, LLC | 6.69% | 1.52M | $2.85M |
| 4 | Goldman Sachs Group Inc | 6.28% | 1.42M | $2.68M |
| 5 | Blackrock Inc. | 6.26% | 1.42M | $2.67M |
| 6 | Vanguard Capital Management LLC | 4.23% | 958.98K | $1.80M |
| 7 | Catalio Capital Management, LP | 4.15% | 940.86K | $1.77M |
| 8 | Avidity Partners Management, LP | 4.08% | 924.49K | $1.74M |
| 9 | T. Rowe Price Investment Management, Inc. | 3.47% | 786.31K | $1.48M |
| 10 | Two Sigma Investments, LP | 3.07% | 695.26K | $1.31M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KPTI
Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOT0t5RDRaRkF1UDhxc1d0cWstR2FNcEhZejA4ckFQMFltN2xYZWRvdF9uY0duclJwZk5PYXp0SnpfT3lHd3VGNUVyV29wTk41MFdWVWlKVHd3WnBnc1ZQaUx2R0dsQTJSNjE3cHZ3UDBhcEtuSGNjakNGMmp1U0pDbllEUGFET1JmMG0zai…
Karyopharm Therapeutics Stock Price Forecast. Should You Buy KPTI? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE9PbTZCdTMzSzRfdXVrTzRFajE3dUt1emJHajZKdEpFbmxqbllMYW9oVHI0WU1KQ3FhTHROMUk1cjUzbjdyOVZOYg?oc=5" target="_blank">Karyopharm Therapeutics Stock Price Forecast. Should You Buy KPTI?</a…
Israel Englander group discloses new Karyopharm stake (NASDAQ: KPTI) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQUTNCTGtaU0M0MHpMc2tkT3RCN0t6WC1iVnpvOHRXVFAzdkEtaTNnTlMxQzgwUi1aY1dpbk14WGlYOUVJbG5Tc2dpRlVhUkZzWVRjV1Y2MDV4NjU4UEYtQ3F2NUE3ZUNQbWRLSFFaeVRCNkt2d0pwWS0tTTB5SXNfUkxCQ1l6UDZlRTNndz…
$KPTI stock is up 9% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOYWpuMmRGMEg4ZHBNWGxOMVk2OEZvMC12Z2hjTFpjY005Vk1qRU5lSW9kR19sbGwxZ01QSEc1b05EVEhrSDdlUFRsRTBZRU93ZkhlVzZ4NkowcGNsN3BtRlZCWGJUb3VkLTdpT0tPVnBmaUY0SXRZVkl0ZG5Wd0dJWnNlSjA4UVd3Ym9CTH…
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar? - qz.com
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPMF9VTm9XV1VsS0lXV0ZuYTNnVXBGVmZJRTFqdThpQnRjMmlwVXpsOTFSeVBYS0NHUVVhMk04LTNoTHhiTGdMd3ZHUVRoSDRJUVhvRDNLQWdSTjhrMkNUWGdmRTBQXzFYRXZkMWVBd3ZTS2drS1gzYnhiOVR4aE90SUowTkY3Q1h5eXk0aA…
Karyopharm Stock (KPTI) Crashes After Hours: Here's What's Driving the Move - Benzinga
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQa2lTSkV4MnZLWnR4RVFtRHFBWW4yZ0VwVl9pbl9vU2JKUTlkX0xIVzFKMk1QRVk1dzVqTUpoQU1JbGN5dE5OcS0zS1lfNGNBVVhjeVEyZThWQ2lDSHVLLUJIU2JVN2Q3X2tHVl9ZNV9ZMnVNRDZwY1dibWxJWjFvYXUyRDZGTDhlZmliQz…
KPTI — Frequently Asked Questions
What is the current share price of Karyopharm Therapeutics Inc. (KPTI)?
As of 2026-09-19 21:16 PDT, Karyopharm Therapeutics Inc. (KPTI) trades at $1.72 on NasdaqGS. Its 52-week range is $1.72 to $10.67.
What is the market capitalisation of KPTI?
Karyopharm Therapeutics Inc. (KPTI) has a market capitalisation of $39.01M on NasdaqGS.
What is the P/E ratio of KPTI?
KPTI trades at a trailing price-to-earnings (P/E) ratio of -0.12. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.13.
What is the return on equity (ROE) of KPTI?
KPTI has a return on equity (ROE) of 66.92%.
Is KPTI a good stock to buy?
This page provides a data-driven analysis of Karyopharm Therapeutics Inc. (KPTI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.